Non Steroidal Anti Inflammatory Drug (NSAIDS) News and Research

RSS

More studies on risks and benefits of COX-2 inhibitors

A group of studies published in the January 24 issue of Archives of Internal Medicine add to the growing body of medical literature about the cardiovascular risks that may be associated with the class of pain-relieving drugs known as COX-2 inhibitors.

24 Jan 2005

Are NSAIDS enough for cancer pain?

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective in managing cancer pain with few side effects, according to a new review of a number of studies.

24 Jan 2005

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.

20 Jan 2005

Committees will weigh up COX-2 benefits and risks

The U.S. Food and Drug Administration (FDA) has announced a joint public meeting of the agency's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee to be held February 16, 17 and 18, 2005.

16 Jan 2005

Trial of naproxen and celecoxib suspended

Use of study drugs in a large, federally funded Alzheimer prevention trial has been suspended following a decision by the study's leadership on Dec. 17, 2004.

9 Jan 2005

Night-time splinting can effectively improve discomfort from early symptoms of carpal tunnel syndrome

After a long day on the job, tired minds and sore feet look forward to a long night of rejuvenating rest. A new study finds that nocturnal rest can do a world of good for your hands and wrists too, especially if you are one of the millions of American workers who are just beginning to feel the common pain and discomfort linked to carpal tunnel syndrome.

5 Jan 2005

Chronic users NSAIDs have greater risk of bleeding and visible damage to their small intestine

According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, chronic users of non-steroidal anti-inflammatory drugs (NSAIDs) have an increased risk of bleeding and visible damage to their small intestine.

4 Jan 2005

Laser therapy may be considered by arthritis patients as a safe Vioxx alternative

Adverse events of long term medication with NSAIDs and particularly coxibs, has recently received much attention in the Vioxx matter. Consequently, Vioxx has been withdrawn and Prexige has been withheld from the market. The whole group of coxibs, are now under special observation by drug agencies in both Europe and the United States.

27 Dec 2004

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

Advice for patients who have been taking Celebrex or Bextra

The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Risk of having a heart attack is elevated in the weeks after stopping use of nonsteroidal anti-inflammatory drugs

The risk of having a heart attack is elevated in the weeks after stopping use of nonsteroidal anti-inflammatory drugs, according to an article in the December issue of The Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Dec 2004

Celebrex like gene suppresses the growth of colon cancer

Cancer researchers at the Case Western Reserve University (Case) School of Medicine, University Hospitals of Cleveland (UHC) and the Howard Hughes Medical Institute have found a "Celebrex-like" gene that suppresses the growth of colon cancer.

13 Dec 2004

Greater risk of heart attack associated with Vioxx than Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.

8 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Indoprofen may lead to new treatments for spinal muscular atrophy

A drug withdrawn from pharmacy shelves over 20 years ago may point the way to a new treatment for spinal muscular atrophy, or SMA, a muscle-wasting and often life-threatening childhood disease.

29 Nov 2004

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Forest Laboratories have announced that Combunox (Oxycodone HCl and Ibuprofen) Tablets (CII), the first and only fixed-dose combination of the opioid oxycodone HCl (5 mg) and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (400 mg), was approved by the U.S. Food and Drug Administration (FDA) for the short-term management of acute, moderate to severe pain.

29 Nov 2004

Topical cream alternative to Vioxx

A clinical study recently published in The Journal of Rheumatology concludes that a topical cream consisting of a blend of natural oils called cetylated fatty acids significantly increased range of motion and physical performance in patients with osteoarthritis of the knee with no reported side effects.

24 Nov 2004

Patients with knee osteoarthritis should avoid long term use of non-steroidal anti-inflammatory drugs

Current guidelines recommend the use of oral NSAIDs in the treatment of knee osteoarthritis and they are used regularly by half of all patients with painful osteoarthritis.

23 Nov 2004

New findings have implications for chronic use of COX-2 Inhibitors in pre-menopausal women

Heart disease is less pronounced in women than in men as humans age, but this difference narrows after menopause. Some studies have shown that estrogen slows heart disease in mouse models, but the mechanism is largely unknown.

18 Nov 2004